Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
MAGL-IN-5
Cat. No.:
OB0225LY-0262
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
MAGL-IN-5 is a selective fatty acid amide hydrolase (MAGL) inhibitor used primarily in the study of the endogenous cannabinoid system.
Synonym:
CAY10499; 359714-55-9; MAGL-IN-5; Benzyl N-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamate; [4-(5-Methoxy-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2-methylphenyl]-carbamic acid, phenylmethyl ester; Benzyl (4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2-methylphenyl)carbamate
CAS No.:
359714-55-9
Compound CID:
9924775
Formula:
C18H17N3O5
Formula Weight:
355.34
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
MAGL-IN-5 can be used in neuroscience research or play an important role in metabolic regulation studies.
Library Information
Targets:
Lipase
Pathways:
Metabolism
Plate Number:
AOCL-4
Plate Location:
c8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
95 mg/mL; 267.35 mM
